Found 44 hits of Enzyme Inhibition Constant Data
Affinity DataEC50: 10nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 1.10E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 80nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: >1.30E+4nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 1.90E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 20nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 20nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 20nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 1.80E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 700nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 200nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 940nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 20nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 600nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 1.50E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 5.70E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 280nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 1.30E+4nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 30nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 590nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 450nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 20nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 150nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 60nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 20nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 2.20E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 1.06E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 2.50E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 1.20E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 600nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 60nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 190nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 30nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 10nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 1.70E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 5.80E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 8nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 30nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 1.40E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 840nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 1.50E+3nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as check point abrogationMore data for this Ligand-Target Pair
Affinity DataEC50: 40nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 40nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair
Affinity DataEC50: 100nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of campothecin induced check pointMore data for this Ligand-Target Pair